Cargando…

The Dynamics of Disease Progression in Cystic Fibrosis

In cystic fibrosis, statistical models have been more successful in predicting mortality than the time course of clinical status. We develop a system of partial differential equations that simultaneously track mortality and patient status, with all model parameters estimated from the extensive and c...

Descripción completa

Detalles Bibliográficos
Autores principales: Adler, Frederick R., Liou, Theodore G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889102/
https://www.ncbi.nlm.nih.gov/pubmed/27248696
http://dx.doi.org/10.1371/journal.pone.0156752
_version_ 1782434947686989824
author Adler, Frederick R.
Liou, Theodore G.
author_facet Adler, Frederick R.
Liou, Theodore G.
author_sort Adler, Frederick R.
collection PubMed
description In cystic fibrosis, statistical models have been more successful in predicting mortality than the time course of clinical status. We develop a system of partial differential equations that simultaneously track mortality and patient status, with all model parameters estimated from the extensive and carefully maintained database from the Cystic Fibrosis Foundation. Cystic fibrosis is an autosomal recessive disease that leads to loss of lung function, most commonly assessed using the Forced Expiratory Volume in 1 second (FEV1%). This loss results from inflammation secondary to chronic bacterial infections, particularly Pseudomonas aeruginosa, methicillin-sensitive Staphylococcus aureus (MSSA) and members of the virulent Burkholderia complex. The model tracks FEV1% and carriage of these three bacteria over the course of a patient’s life. Analysis of patient state changes from year to year reveals four feedback loops: a damaging positive feedback loop between P. aeruginosa carriage and lower FEV1%, negative feedback loops between P. aeruginosa and MSSA and between P. aeruginosa and Burkholderia, and a protective positive feedback loop between MSSA carriage and higher FEV1%. The partial differential equations built from this data analysis accurately capture the life-long progression of the disease, quantify the key role of high annual FEV1% variability in reducing survivorship, the relative unimportance of short-term bacterial interactions for long-term survival, and the potential benefits of eradicating the most harmful bacteria.
format Online
Article
Text
id pubmed-4889102
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-48891022016-06-10 The Dynamics of Disease Progression in Cystic Fibrosis Adler, Frederick R. Liou, Theodore G. PLoS One Research Article In cystic fibrosis, statistical models have been more successful in predicting mortality than the time course of clinical status. We develop a system of partial differential equations that simultaneously track mortality and patient status, with all model parameters estimated from the extensive and carefully maintained database from the Cystic Fibrosis Foundation. Cystic fibrosis is an autosomal recessive disease that leads to loss of lung function, most commonly assessed using the Forced Expiratory Volume in 1 second (FEV1%). This loss results from inflammation secondary to chronic bacterial infections, particularly Pseudomonas aeruginosa, methicillin-sensitive Staphylococcus aureus (MSSA) and members of the virulent Burkholderia complex. The model tracks FEV1% and carriage of these three bacteria over the course of a patient’s life. Analysis of patient state changes from year to year reveals four feedback loops: a damaging positive feedback loop between P. aeruginosa carriage and lower FEV1%, negative feedback loops between P. aeruginosa and MSSA and between P. aeruginosa and Burkholderia, and a protective positive feedback loop between MSSA carriage and higher FEV1%. The partial differential equations built from this data analysis accurately capture the life-long progression of the disease, quantify the key role of high annual FEV1% variability in reducing survivorship, the relative unimportance of short-term bacterial interactions for long-term survival, and the potential benefits of eradicating the most harmful bacteria. Public Library of Science 2016-06-01 /pmc/articles/PMC4889102/ /pubmed/27248696 http://dx.doi.org/10.1371/journal.pone.0156752 Text en © 2016 Adler, Liou http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Adler, Frederick R.
Liou, Theodore G.
The Dynamics of Disease Progression in Cystic Fibrosis
title The Dynamics of Disease Progression in Cystic Fibrosis
title_full The Dynamics of Disease Progression in Cystic Fibrosis
title_fullStr The Dynamics of Disease Progression in Cystic Fibrosis
title_full_unstemmed The Dynamics of Disease Progression in Cystic Fibrosis
title_short The Dynamics of Disease Progression in Cystic Fibrosis
title_sort dynamics of disease progression in cystic fibrosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889102/
https://www.ncbi.nlm.nih.gov/pubmed/27248696
http://dx.doi.org/10.1371/journal.pone.0156752
work_keys_str_mv AT adlerfrederickr thedynamicsofdiseaseprogressionincysticfibrosis
AT lioutheodoreg thedynamicsofdiseaseprogressionincysticfibrosis
AT adlerfrederickr dynamicsofdiseaseprogressionincysticfibrosis
AT lioutheodoreg dynamicsofdiseaseprogressionincysticfibrosis